UCPVax

P2, N=105, Recruiting, Centre Hospitalier Universitaire de Besancon | Trial completion date: Sep 2029 --> Feb 2030 | Trial primary completion date: Apr 2025 --> Mar 2028

These findings highlight UCPVax as an off-the-shelf helper platform to enhance therapeutic cancer vaccine efficacy. This study was registered at ClinicalTrials.gov: NCT02818426.

P2, N=105, Recruiting, Centre Hospitalier Universitaire de Besancon | Trial completion date: Sep 2027 --> Sep 2029

P2, N=60, Completed, Centre Hospitalier Universitaire de Besancon | Active, not recruiting --> Completed | N=111 --> 60 | Trial completion date: Sep 2025 --> Nov 2024

P2, N=67, Completed, Centre Hospitalier Universitaire de Besancon | Active, not recruiting --> Completed

P1/2, N=82, Completed, Centre Hospitalier Universitaire de Besancon | Active, not recruiting --> Completed | N=54 --> 82

P1/2, N=54, Active, not recruiting, Centre Hospitalier Universitaire de Besancon | Trial completion date: Dec 2023 --> Dec 2024

While DNA vaccines demonstrate promising immunogenicity, peptide vaccines, such as UV1, UCPVax, and Vx-001, have shown clinical efficacy in certain cancer types. Accordingly, we discuss the mechanisms of action, preclinical and clinical data, and the potential of these vaccines to elicit robust and durable anti-tumor immune responses. This review highlights the potential of telomerase-based vaccines as a promising strategy for cancer treatment and identifies areas for future research.

P2, N=47, Completed, Centre Hospitalier Universitaire de Besancon | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Nov 2024 | Trial primary completion date: Sep 2024 --> Mar 2024

One month after completion of radiation/ temozolomide (TMZ), patients started UCPvax vaccinations on days 1, 8, 15, 29, 36 and 43, then every two months until tumor progression. In this population of unmethylated MGMT GBM patients, UCPVax is highly immunogenic and provides an interesting OS rate. These data strongly support the completion of the second ongoing cohort, assessing UCPvax in combination with TMZ for GBM patients with methylated MGMT promoter status.

Combining anti-PD-1/PD-L1 therapy with an anti-telomerase vaccine gains serious consideration in HCC, in order to extend the clinical efficacy of anti-PD-1/PD-L1. Indeed, anti-cancer vaccines can induce tumor-specific T cell expansion and activation and therefore restore the cancer-immunity cycle in patients lacking pre-existing anti-tumor responses. Thus, there is a strong rational to combine immune checkpoint blockade therapy and anticancer vaccine (UCPVax) in order to activate antitumor T cell immunity and bypass the immunosuppression in the tumor microenvironment in HCC. This pivotal proof of concept study will evaluate the efficacy and safety of the combination of a CD4 Th1-inducer cancer vaccine derived from telomerase (UCPVax) and atezolizumab plus bevacizumab in unresectable HCC, as well as confirming their synergic mechanism, and settling the basis for a new combination for future clinical trials.

P2, N=56, Active, not recruiting, Centre Hospitalier Universitaire de Besancon | Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Dec 2024 | Trial primary completion date: Nov 2022 --> Dec 2023